Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HIMA LOBBYING IN SUPPORT OF DEVICE USER FEE BILL

This article was originally published in The Gray Sheet

Executive Summary

HIMA LOBBYING IN SUPPORT OF DEVICE USER FEE BILL is focused on key members of the House and Senate committees that will consider the measure. The Health Industry Manufacturers Association is attempting to persuade opponents of the bill, introduced July 12, not to set up obstacles to its passage, arguing that if the measure fails Congress could end up adopting legislation that is less friendly to industry.

You may also be interested in...



Device Reforms At Crossroads: Will User Fee Momentum Reach Critical Mass?

Device user fee advocates have a window of opportunity in which to capitalize on support from Senate HELP Committee leaders in pushing the proposal through Prescription Drug User Fee Act reauthorization this year

Device User Fees On The Table For PDUFA III: Senate Cmte. In Discussions

Senate Health, Education, Labor & Pensions (HELP) Committee staffers are actively considering device user fee language for inclusion in the Prescription Drug User Fee Act reauthorization this year

Device User Fees On The Table For PDUFA III: Senate Cmte. In Discussions

Senate Health, Education, Labor & Pensions (HELP) Committee staffers are actively considering device user fee language for inclusion in the Prescription Drug User Fee Act reauthorization this year

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel